KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

High Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.

Chiyu He, Kankai Zhu, Qingqu Guo, Li Chen, Dan Wu, Lele Lin, Xiaoyong Zhang, Qianyun Shen, Weihuai Liu, Qi Zhang, Xinbao Wang, Ping Hu, Zhiqiang Zheng, Xianfa Wang, Zhilong Yan, Qing Zhang, Chunhui Shou, Yongqiang Si, Xingnan Wu, Tianzhe Gao, Yuan Gao, Jiren Yu, Xiaosun Liu

J Cachexia Sarcopenia Muscle 16(6) e70107

PMID41168973
PMCIDPMC12575444
DOI10.1002/jcsm.70107
发表日期2025-10-31
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Gastric cancer (GC) patients often have nutritional risks or malnutrition, and neoadjuvant chemotherapy (NAC) tends to exacerbate malnutrition. Body composition parameters are associated with the prognosis of GC patients. Little is known about body composition changes during NAC and its role in clinical outcomes. METHODS: This was a secondary analysis of a Phase 3, open-label, multicentre, randomized clinical trial (RCT) (NCT01364376), assessing the usefulness, safety and efficacy of S-1 plus oxaliplatin (SOX) vs. fluorouracil, leucovorin and oxaliplatin (FOLFOX) as a perioperative chemotherapy regimen for patients with locally advanced GC. Pre-NAC and post-NAC computer tomography (CT) were collected to evaluate the prognostic role of skeletal muscle, adipose tissue and their dynamic change. Overall survival (OS) and progression-free survival (PFS) rates were calculated using the Kaplan-Meier method. RESULTS: A total of 583 patients from 12 Chinese hospitals were enrolled. After exclusion, 423 patients who proceeded to surgery were used for further analysis. The median age was 60 (IQR: 54, 66) years, and 133 patients (31.4%) were female. Prior to NAC, 132 (31.2%) patients were diagnosed with sarcopenia. There was no significant difference in overall survival between sarcopenia and non-sarcopenia patients (p = 0.363). During NAC, most patients suffered skeletal muscle (SM) loss (n = 268, 63.4%), subcutaneous adipose tissue (SAT) loss (n = 236, 55.8%) and visceral adipose tissue (VAT) loss (n = 254, 60.0%). Patients with SAT loss > 12.5% had significantly worse PFS (p = 0.005) and OS (p = 0.003) than those without. Patients with VAT loss > 15% had significantly worse PFS (p = 0.003) and OS (p = 0.004) than the stable or gain group. Patients with SMI loss > 4.7% had significantly worse PFS (p = 0.043) and showed a tendency of reduced OS (p = 0.181) than those without. In patients without sarcopenia, the incidence of grade 3/4 neutropenia in the FOLFOX group was higher than that of the SOX group (p = 0.019). In patients with myosteatosis, the incidence of Grade 3/4 thrombocytopenia in the SOX group was higher than that of the FOLFOX group (p < 0.001). CONCLUSION: In this RCT study, patients with GC experience significant losses of muscle and adipose tissue during NAC. A high level of adipose tissue or muscle loss during NAC is prognostic of reduced survival in patients with locally advanced GC. Assessing and monitoring body composition can predict prognosis and effectively guide individual nutrition intervention and the prevention of complications.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

FIGURE 4

FIGURE 4 Kaplan–Meier curves for high loss group and stable or gain group. (A) PFS according to SATI loss. (B) OS according to SATI loss. (C) PFS according to VATI loss. (D) OS according to VATI loss. (E) PFS according to SMI loss. (F) OS according to SMI loss. OS, overall survival; PFS, progression‐free survival; SATI, subcutaneous adipose tissue index; SMI, skeletal muscle index; VATI, visceral adipose tissue index.

A

PFS

FIGURE 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIGURE 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

PFS

FIGURE 4 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

FIGURE 4 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

PFS

FIGURE 4 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
F

OS

FIGURE 4 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Flowchart of patient selection procedures. CT, computed tomography; FOLFOX, fluorouracil, leucovorin and oxaliplatin; SOX, S‐1 plus oxaliplatin.
非 KM Figure
FIGURE 2FIGURE 2 Cross‐section of pre‐NAC and post‐NAC CT‐scan images at the L3 region from the same patient. (A) Pre‐NAC. (B) Post‐NAC. Red: skeletal muscle; blue: subcutaneous adipose tissue; yellow: visceral adipose tissue. CT, computed tomography; NAC, neoadjuvant chemotherapy.
非 KM Figure
FIGURE 3FIGURE 3 Dynamic change of body composition parameters before and after the NAC. Comparison of SMI (A), SATI (B) and VATI (C) before and after the NAC. Change of SMI (D), SATI (E) and VATI (F) in SOX and FOLFOX group. * p < 0.05, ** p < 0.01. FOLFOX, fluorouracil, leucovorin and oxaliplatin; NAC, neoadjuvant chemotherapy; SATI, subcutaneous adipose tissue index; SMI, skeletal muscle index; SOX, S‐1 and oxaliplatin; VATI, visceral adipose tissue index.
非 KM Figure